257 related articles for article (PubMed ID: 30854783)
1. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
[TBL] [Abstract][Full Text] [Related]
2. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
3. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
[No Abstract] [Full Text] [Related]
4. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Depré F; Aboud N; Mayer B; Salama A
Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
[TBL] [Abstract][Full Text] [Related]
6. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
[No Abstract] [Full Text] [Related]
7. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
8. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
[No Abstract] [Full Text] [Related]
11. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
[No Abstract] [Full Text] [Related]
12. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
14. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Neunert CE; Rose MJ
Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
Meyer O; Richter H; Lebioda A; Schill M
Hematology; 2021 Dec; 26(1):697-708. PubMed ID: 34547980
[TBL] [Abstract][Full Text] [Related]
16. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
17. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.
Suntsova EV; Demina IM; Ignatova AA; Ershov NM; Trubina NM; Dobrynina J; Serkova IV; Supik ZS; Orekhova EV; Hachatryan LA; Kotskaya NN; Pshonkin AV; Maschan AA; Novichkova GA; Panteleev MA
Int J Hematol; 2017 Jun; 105(6):841-848. PubMed ID: 28271416
[TBL] [Abstract][Full Text] [Related]
18. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
20. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
